Publications by authors named "Shing M Lee"

Claim this Profile
I
Incorporating patient-reported outcomes in dose-finding clinical trials with continuous patient enrollment.
Anaïs Andrillon, Lucie Biard, Shing M Lee

J Biopharm Stat· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pragmatic, multicentre, factorial, randomised controlled trial of sepsis electronic prompting for timely intervention and care (SEPTIC trial): a protocol.
Benjamin L Ranard, Min Qian, Matthew J Cummings, David Y Zhang, Shing M Lee

BMJ Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Individualization for Phase I Cancer Trials With Broadened Eligibility.
Rebecca B Silva, Bin Cheng, Richard D Carvajal, Shing M Lee

Stat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose optimization for cancer treatments with considerations for late-onset toxicities.
Lucie Biard, Anaïs Andrillon, Rebecca B Silva, Shing M Lee

Clin Trials· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).
Shing M Lee, Weijia Fan, Aijin Wang, Riha Vaidya, Mary W Redman

JCO Clin Cancer Inform· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
Anaïs Andrillon, Sylvie Chevret, Shing M Lee, Lucie Biard

Stat Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.
Joseph M Unger, Riha Vaidya, Kathy S Albain, Michael LeBlanc, Lori M Minasian, Shing M Lee

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
Rebecca B Silva, Christina Yap, Richard Carvajal, Shing M Lee

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What do we do with our under-enrolled single-center COVID-19 clinical trials?
Shing M Lee, Denise Esserman, Ken Cheung, James Dziura, Peter Peduzzi

Clin Trials· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to M. Ratain.
Shing M Lee, Nolan A Wages, Karyn A Goodman, A Craig Lockhart

JCO Precis Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors.
Gulam A Manji, Brian A Van Tine, Shing M Lee, Alexander G Raufi, Ilenia Pellicciotta

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Misalignment between COVID-19 hotspots and clinical trial sites.
Lauren Franks, Hao Liu, Mitchell S V Elkind, Muredach P Reilly, Chunhua Weng, Shing M Lee

J Am Med Inform Assoc· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying normal lung in pulmonary fibrosis: CT analysis and correlation with %DLCO.
Kathleen M Capaccione, Aijin Wang, Shing M Lee, Nina Patel, John H M Austin

Clin Imaging· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Seamless phase I/II design for novel anticancer agents with competing disease progression.
Lucie Biard, Shing M Lee, Bin Cheng

Stat Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
Julia E McGuinness, Mirella L Altoe, Alessandro Marone, Lauren E Franks, Shing M Lee

Breast Cancer Res Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simulation study of approaches for handling disease progression in dose-finding clinical trials.
Lucie Biard, Bin Cheng, Gulam A Manji, Shing M Lee

J Biopharm Stat· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials.
Jae Hyun Kim, Casey N Ta, Cong Liu, Cynthia Sung, Alex M Butler, Junghwan Lee, Shing M Lee

J Am Med Inform Assoc· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.
Shing M Lee, Nolan A Wages, Karyn A Goodman, A Craig Lockhart

JCO Precis Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding design and benchmark for a right censored endpoint.
Anaïs Andrillon, Sylvie Chevret, Shing M Lee, Lucie Biard

J Biopharm Stat· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
Guarionex J DeCastro, Wilson Sui, Jamie S Pak, Shing M Lee, Dara Holder

J Urol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer.
Kathleen Fenn, Matthew Maurer, Shing M Lee, Katherine D Crew, Meghna S Trivedi

Clin Breast Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating patient-reported outcomes in dose-finding clinical trials.
Shing M Lee, Xiaoqi Lu, Bin Cheng

Stat Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events.
Shing M Lee, Jieling Miao, Ruby Wu, Joseph M Unger, Ken Cheung

Health Qual Life Outcomes· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding designs for cumulative toxicities using multiple constraints.
Shing M Lee, Moreno Ursino, Ying Kuen Cheung, Sarah Zohar

Biostatistics· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating global treatment toxicity burden from adverse-event data.
Shing M Lee, Dawn L Hershman, Jieling Miao, Xiaobo Zhong, Joseph M Unger

Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis